IKBKE is induced by STAT3 and tobacco carcinogen and determines chemosensitivity in non-small cell lung cancer

J Guo1, D Kim, J Gao

  • 1Department of Molecular Oncology, H Lee Moffitt Cancer Center, Tampa, FL 33612, USA.

Oncogene
|February 15, 2012
PubMed

Insights

The oncogene IKBKE is regulated by signal transducer and activator of transcription 3 (STAT3). Tobacco carcinogens like nicotine induce IKBKE via STAT3, impacting lung cancer chemoresistance and survival.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Serine/threonine kinase IKBKE is an oncogene with poorly understood regulation.
  • Signal transducer and activator of transcription 3 (STAT3) is a key signaling pathway in cancer.

Purpose of the Study:

  • To elucidate the regulation of IKBKE.
  • To investigate the role of STAT3 in IKBKE expression.
  • To determine the impact of tobacco components on IKBKE and its role in non-small cell lung cancer (NSCLC).

Main Methods:

  • Investigated IKBKE expression in relation to STAT3 activation and tobacco use in NSCLC patients.
  • Utilized cell culture models to study the effects of nicotine and NNK on IKBKE.
  • Performed promoter analysis to identify STAT3-binding elements.
  • Assessed the role of IKBKE in chemoresistance and cell survival through gene expression manipulation.

Main Results:

  • IKBKE is a direct downstream target of STAT3, with STAT3 activation increasing IKBKE expression.
  • Tobacco components, nicotine and NNK, induce IKBKE expression through the STAT3 pathway.
  • IKBKE expression correlates with STAT3 activation and smoking history in NSCLC patients.
  • IKBKE promotes chemoresistance and cell survival, while its inhibition sensitizes NSCLC cells to chemotherapy.

Conclusions:

  • IKBKE is a direct STAT3 target induced by tobacco carcinogens via the STAT3 pathway.
  • IKBKE plays a significant role in tobacco-associated lung carcinogenesis and chemoresistance.
  • IKBKE represents a potential therapeutic target for NSCLC.

Related Concept Videos

Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...